A nurse is teaching about the purpose of epoetin alfa to client who has chronic kidney disease. Which statement by the client demonstrates understanding of the purpose of this medication?

A. Epoetin alfa does not affect coagulation or platelet function. Medications that influence blood clotting, such as warfarin or heparin, are unrelated to erythropoiesis-stimulating agents. Epoetin alfa’s primary role is stimulating red blood cell production, not altering clotting pathways. B. Epoetin alfa does not replace iron. Chronic kidney disease can lead to iron deficiency because of reduced absorption, dietary restrictions, or blood loss during dialysis. Clients may need iron supplementation to support the increased red blood cell production stimulated by epoetin alfa, but the drug itself does not provide iron. C. Epoetin alfa does not increase white blood cell counts. Its action is specific to the erythroid lineage in the bone marrow, targeting red blood cell production to correct anemia. White blood cell counts and immune function are unaffected by this medication. D. Epoetin alfa is an erythropoiesis-stimulating agent (ESA) that mimics the natural hormone erythropoietin, which is normally produced by the kidneys. In chronic kidney disease, reduced erythropoietin levels lead to anemia, characterized by fatigue, pallor, and decreased oxygen delivery to tissues. Epoetin alfa acts on the bone marrow to stimulate the production of red blood cells, thereby improving oxygen-carrying capacity, energy levels, and overall quality of life. Clients receiving this medication may also require concurrent iron, folic acid, or vitamin B12 supplementation to ensure adequate substrate for effective erythropoiesis.